• Sanara Medtech Inc SMTI.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of two analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -70 cents to -31 cents per share.

• Revenue rose 26.4% to $23.43 million from a year ago; analysts expected $23.48 million.

• Sanara Medtech Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $3.53 million.

• Sanara Medtech Inc shares had risen by 13.7% this quarter and gained 5.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 90.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Sanara Medtech Inc is $48.50

This summary was machine generated from LSEG data May 14 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)